Testing CSL222 (AAV5-hFIXco-Padua) for hemophilia b

Exclusion

• −Known history of allergy to corticosteroids or known medical condition that would require chronic administration of oral corticosteroids.
• −Known uncontrolled allergic conditions or allergy / hypersensitivity to any component of the CSL222 excipients (ie, sucrose, potassium chloride, potassium dihydrogen phosphate, sodium chloride, and disodium hydrogen phosphate).
• −Any uncontrolled or untreated infection (human immunodeficiency virus \[HIV\], hepatitis B virus \[HBV\] and hepatitis C virus \[HCV\], or any other significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, cardiovascular, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease, alcoholism, drug dependency, or any other psychological disorder evaluated by the investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more → to interfere with adherence to the clinical study protocolProtocolThe detailed plan a study must follow.Read more → procedures or with the degree of tolerance to CSL222.
• −History of FIX inhibitors or positive FIX inhibitor test at Prescreening, ScreeningScreeningThe checks done before joining, to see whether a study fits.Read more → or Visit L-Final (based on central laboratory results).
• −Screening or Visit L-Final laboratory values (based on central laboratory results) of total bilirubin \> 2 × the upper limit of normal (ULN) (except if caused by Gilbert's syndrome).
• −Screening or Visit L-Final laboratory values (based on central laboratory results) of any of the following laboratory abnormalities:
• −ALT \> 2 × the ULN
• −AST \> 2 × the ULN
• −Alkaline phosphatase \> 2 × the ULN
• −Serum creatinine \> 2 × the ULN
• −Hemoglobin less than (\<) 8 g/dL
• −Any condition other than hemophilia B resulting in an increased bleeding tendency.
• −Thrombocytopenia, defined as a platelet count \<50 × 10\^9/L, at Screening or Visit L Final (based on central laboratory results).
• −Previous AAV5 gene therapy treatment.
• −Receipt of an experimental agent or device within 60 days before Screening until the end of the study.